ZAI LAB LIMITED Tax Withholding Paid on Stock Awards
ZAI LAB LIMITED (ZLAB) reported Tax Withholding Paid on Stock Awards of $4.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $2.20M, a 8055.56% increase year-over-year.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $2.27M.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $8.19M.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for fiscal 2025 was $8.22M.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for fiscal 2023 was $8.80M, a 15.82% increase from fiscal 2022.
- ZAI LAB LIMITED payment, tax withholding, share-based payment arrangement for fiscal 2022 was $7.60M, a 78.70% increase from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.47M 10-Q · filed 2026-08-06 | $4.47M derived: sum of 3 quarters · filed 2026-08-06 | $12.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.27M 10-Q · filed 2026-05-07 | $2.27M derived: sum of 2 quarters · filed 2026-05-07 | $10.46M derived: sum of 3 quarters · filed 2026-05-07 | $10.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.19M derived: sum of 2 quarters · filed 2026-02-26 | $8.22M derived: sum of 3 quarters · filed 2026-08-06 | $8.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.22M derived: sum of 2 quarters · filed 2026-08-06 | $8.22M 10-Q · filed 2025-11-06 | $8.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $27.00K 10-Q · filed 2026-08-06 | $27.00K derived: sum of 3 quarters · filed 2026-08-06 | $27.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $77.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $77.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $77.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.66M derived: sum of 3 quarters · filed 2026-02-26 | $3.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.66M derived: sum of 2 quarters · filed 2026-02-26 | $3.72M derived: sum of 3 quarters · filed 2026-02-26 | $8.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.64M derived: sum of 2 quarters · filed 2024-11-12 | $8.72M 10-Q · filed 2024-11-12 | $9.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $7.14M 10-Q · filed 2024-08-06 | $7.57M derived: sum of 3 quarters · filed 2025-02-27 | $7.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.08M 10-Q · filed 2024-05-08 | $5.51M derived: sum of 2 quarters · filed 2025-02-27 | $5.82M derived: sum of 3 quarters · filed 2025-02-27 | |
| 2022-12-31 | $429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $741.00K derived: sum of 2 quarters · filed 2025-02-27 | $7.60M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $312.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.17M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $6.86M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $4.25M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |